139 related articles for article (PubMed ID: 16435338)
1. A pattern-mixture model for the analysis of censored quality-of-life data.
Li H; Heitjan DF
Stat Med; 2006 May; 25(9):1533-46. PubMed ID: 16435338
[TBL] [Abstract][Full Text] [Related]
2. Bayesian estimation of cost-effectiveness from censored data.
Heitjan DF; Kim CY; Li H
Stat Med; 2004 Apr; 23(8):1297-309. PubMed ID: 15083484
[TBL] [Abstract][Full Text] [Related]
3. Placebo effect-adjusted assessment of quality of life in placebo-controlled clinical trials.
Eickhoff JC
Stat Med; 2008 Apr; 27(9):1387-402. PubMed ID: 18219702
[TBL] [Abstract][Full Text] [Related]
4. Improving outcomes with long-term "destination" therapy using left ventricular assist devices.
Long JW; Healy AH; Rasmusson BY; Cowley CG; Nelson KE; Kfoury AG; Clayson SE; Reid BB; Moore SA; Blank DU; Renlund DG
J Thorac Cardiovasc Surg; 2008 Jun; 135(6):1353-60; discussion 1360-1. PubMed ID: 18544385
[TBL] [Abstract][Full Text] [Related]
5. [Economic impact of cardiac resynchronization therapy in patients with heart failure. Available evidence and evaluation of the CRT-Eucomed model for analysis of cost-effectiveness].
Fattore G; Landolina M; Bontempi L; Cacciatore G; Curnis A; Gulizia M; Padeletti L; Mazzei L; Tavazzi L;
Ital Heart J Suppl; 2005 Dec; 6(12):796-803. PubMed ID: 16444923
[TBL] [Abstract][Full Text] [Related]
6. Prediction of event times in the REMATCH Trial.
Ying GS; Heitjan DF
Clin Trials; 2013 Apr; 10(2):197-206. PubMed ID: 23321264
[TBL] [Abstract][Full Text] [Related]
7. Bayesian model selection: analysis of a survival model with a surviving fraction.
Seltman H; Greenhouse J; Wasserman L
Stat Med; 2001 Jun; 20(11):1681-91. PubMed ID: 11391695
[TBL] [Abstract][Full Text] [Related]
8. Composite measures for hospital quality using quality-adjusted life years.
Timbie JW; Shahian DM; Newhouse JP; Rosenthal MB; Normand SL
Stat Med; 2009 Apr; 28(8):1238-54. PubMed ID: 19184974
[TBL] [Abstract][Full Text] [Related]
9. Pattern mixture models for longitudinal quality of life studies in advanced stage disease.
Pauler DK; McCoy S; Moinpour C
Stat Med; 2003 Mar; 22(5):795-809. PubMed ID: 12587106
[TBL] [Abstract][Full Text] [Related]
10. Bayesian transformation cure frailty models with multivariate failure time data.
Yin G
Stat Med; 2008 Dec; 27(28):5929-40. PubMed ID: 18618427
[TBL] [Abstract][Full Text] [Related]
11. Baseline and treatment effect heterogeneity for survival times between centers using a random effects accelerated failure time model with flexible error distribution.
Komárek A; Lesaffre E; Legrand C
Stat Med; 2007 Dec; 26(30):5457-72. PubMed ID: 17910009
[TBL] [Abstract][Full Text] [Related]
12. A quality-adjusted survival (Q-TWiST) model for evaluating treatments for advanced stage cancer.
Cole BF; Gelber RD; Gelber S; Mukhopadhyay P
J Biopharm Stat; 2004 Feb; 14(1):111-24. PubMed ID: 15027503
[TBL] [Abstract][Full Text] [Related]
13. Long-term survivor mixture model with random effects: application to a multi-centre clinical trial of carcinoma.
Yau KK; Ng AS
Stat Med; 2001 Jun; 20(11):1591-607. PubMed ID: 11391690
[TBL] [Abstract][Full Text] [Related]
14. Multiple augmentation for interval-censored data with measurement error.
Song X; Ma S
Stat Med; 2008 Jul; 27(16):3178-90. PubMed ID: 18040984
[TBL] [Abstract][Full Text] [Related]
15. Bayesian methods for analysis of binary outcome data in cluster randomized trials on the absolute risk scale.
Thompson SG; Warn DE; Turner RM
Stat Med; 2004 Feb; 23(3):389-410. PubMed ID: 14748035
[TBL] [Abstract][Full Text] [Related]
16. A multistate Markov chain model for longitudinal, categorical quality-of-life data subject to non-ignorable missingness.
Cole BF; Bonetti M; Zaslavsky AM; Gelber RD
Stat Med; 2005 Aug; 24(15):2317-34. PubMed ID: 15977292
[TBL] [Abstract][Full Text] [Related]
17. Bayesian estimation of cost-effectiveness: an importance-sampling approach.
Heitjan DF; Li H
Health Econ; 2004 Feb; 13(2):191-8. PubMed ID: 14737756
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection.
Lietz K; Long JW; Kfoury AG; Slaughter MS; Silver MA; Milano CA; Rogers JG; Naka Y; Mancini D; Miller LW
Circulation; 2007 Jul; 116(5):497-505. PubMed ID: 17638928
[TBL] [Abstract][Full Text] [Related]
19. Predicting analysis times in randomized clinical trials.
Bagiella E; Heitjan DF
Stat Med; 2001 Jul; 20(14):2055-63. PubMed ID: 11439420
[TBL] [Abstract][Full Text] [Related]
20. Predicting event times in clinical trials when randomization is masked and blocked.
Donovan JM; Elliott MR; Heitjan DF
Clin Trials; 2007; 4(5):481-90. PubMed ID: 17942464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
